Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with several Chinese healthcare firms, including iKang Healthcare Group, Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), V-Medical, Kindstar Global (HKG: 9960), and Ribose. These collaborations are aimed at tapping into the Alzheimer’s disease (AD) market in China.
Eisai’s AD therapy, Leqembi (lecanemab), received approval in China to treat patients with mild cognitive impairment (MCI) due to AD and/or mild AD dementia in January this year and was launched in early July. Leqembi, a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, is recognized as the world’s first targeted drug addressing the pathology of Alzheimer’s disease.
iKang Healthcare, a leading preventative medicine company, introduced a groundbreaking blood testing product in 2024 that can predict the onset of Alzheimer’s disease 5-7 years before clinical symptoms manifest, through a simple blood draw during a routine check-up. Zhejiang Dian Diagnostics has developed a comprehensive detection system that covers the entire spectrum of Alzheimer’s disease. V-Medical is focused on advancing the diagnosis and treatment timeline for AD. Kindstar Global, a major high-end medical specialty testing service and inspection group in China, and Ribose, one of China’s earliest third-party laboratories to adopt Simoa technology from the United States, are also part of this strategic alliance, aiming to enhance AD diagnosis and management services in the country.- Flcube.com
